Sept. 21 marks Dementia Overcoming Day, a designated observance created to raise public awareness about preventing and managing cognitive decline. The date also coincides with World Alzheimer’s Day, established jointly by the World Health Organization (WHO) and Alzheimer’s Disease International (ADI).
While dementia and Alzheimer’s disease are often used synonymously in public discourse, they represent distinct clinical concepts. Dementia is an overarching umbrella term describing a cluster of symptoms where cognitive decline—spanning memory, language, and executive function—severely impairs an individual's ability to perform daily activities independently. Alzheimer’s disease is the leading cause of dementia, characterized by progressive neurodegeneration and structural brain cell damage. However, dementia can also stem from vascular disease, Lewy body disease, or other neurological conditions.
Experts stress that identifying early signs of cognitive decline and pinpointing their root causes are critical before irreversible brain damage occurs. Among older adults, mild cognitive impairment (MCI) represents a crucial window for assessment and intervention.
Often described as a "pre-dementia stage," MCI does not automatically progress to full-blown dementia. Rather than a single disease entity, MCI represents a broad clinical state in which cognitive function has declined due to a variety of underlying causes. The primary distinction between MCI and dementia lies in the preservation of functional independence.
"Mild cognitive impairment is a condition where cognitive functions such as memory, language, attention, and judgment have noticeably declined compared to baseline, yet the individual maintains the ability to manage daily life independently—such as taking medications, handling finances, and using public transportation," said Kang Dong-woo, a professor of psychiatry at Seoul St. Mary’s Hospital. "This contrasts sharply with dementia, where functional independence is clearly compromised."
Progression Rates and Modifiable Risk Factors
The progression rate from MCI to dementia varies widely among individuals. According to a 2025 meta-analysis published in Alzheimer’s & Dementia by an Italian research team—which synthesized 89 studies involving 33,115 MCI patients over an average follow-up of 5.2 years—41.5% of patients in specialty clinic settings and 27% in community settings progressed to dementia, representing annual conversion rates of 10.9% and 5.9%, respectively. Crucially, a significant proportion of participants maintained stable cognitive function, and some even reverted to normal cognitive status.
Consequently, clinicians evaluating MCI must focus on determining the specific drivers of cognitive decline rather than attempting solely to predict progression. Comprehensive evaluations should combine detailed medical histories and functional assessments with standardized neurocognitive testing, blood panels, and brain magnetic resonance imaging (MRI).
Lifestyle interventions at the MCI stage yield measurable benefits. In the US POINTER trial, a large-scale clinical study involving 2,111 adults aged 60 to 79 at elevated risk for cognitive decline, participants who received structured, multi-domain interventions—combining exercise, dietary adjustments, cognitive engagement, and cardiovascular monitoring—demonstrated significantly greater cognitive improvements over two years compared to those following self-directed programs.
"These findings demonstrate that combining multiple lifestyle modifications can yield tangible cognitive improvements in as little as two years," Prof. Kang noted. "Regular physical activity, a diet rich in vegetables, whole grains, legumes, fish, and nuts, along with smoking cessation, moderate alcohol intake, adequate sleep, and active social engagement are vital."
Managing cardiovascular and metabolic conditions such as hypertension, diabetes, and hyperlipidemia is equally critical. In 2024, the Lancet Commission on Dementia updated its list of modifiable risk factors to 14 by adding high low-density lipoprotein (LDL) cholesterol and untreated vision loss to existing factors including low education level, hearing impairment, hypertension, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol consumption, traumatic brain injury, air pollution, and social isolation. Collectively, these 14 factors account for approximately 45% of dementia cases worldwide.
Early Intervention for Confirmed Alzheimer’s Pathology
When diagnostic testing confirms that underlying Alzheimer’s pathology is driving MCI, early therapeutic intervention becomes essential. Pathological changes in the brain often begin 10 to 20 years before clinical symptoms manifest, starting with abnormal amyloid-beta accumulation, followed by tau protein tangles that drive neuronal loss and cognitive decline.
Because damaged neurons cannot be restored, contemporary medical treatments aim to slow disease progression rather than reverse existing deficits. Disease-modifying anti-amyloid therapies, such as lecanemab and donanemab, have demonstrated efficacy in clinical trials by slowing the rate of cognitive and functional decline in patients with MCI or early-stage Alzheimer's disease with confirmed amyloid pathology.
However, these pharmaceutical therapies are not suitable for all MCI patients. "Before initiating treatment, clinicians must confirm the presence of amyloid pathology through specialized testing," Prof. Kang emphasized. "Because these drugs carry risks of adverse events such as amyloid-related imaging abnormalities (ARIA), including brain swelling or microbleeds, thorough evaluation by a specialist and regular MRI monitoring before and during treatment are imperative."
Ultimately, cognitive decline often stems from a multifactorial mix of Alzheimer's pathology, cerebrovascular lesions, depression, sleep disturbances, sensory deficits, and medication side effects. Accurately identifying these contributing factors while aggressively managing modifiable lifestyle and vascular risks remains the most effective strategy for preserving cognitive health.
